KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Financing Activities: 2018-2025

Historic Cash from Financing Activities for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $10.7 million.

  • Esperion Therapeutics' Cash from Financing Activities rose 217.34% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year decrease of 26.70%. This contributed to the annual value of $86.5 million for FY2024, which is 71.39% up from last year.
  • Esperion Therapeutics' Cash from Financing Activities amounted to $10.7 million in Q3 2025, which was up 274.46% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Cash from Financing Activities registered a high of $213.4 million during Q4 2021, and its lowest value of -$30.4 million during Q4 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $2.9 million (2025), whereas its average is $13.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 3,546.52% in 2023, then crashed by 3,811.12% in 2024.
  • Esperion Therapeutics' Cash from Financing Activities (Quarterly) stood at $213.4 million in 2021, then plummeted by 114.23% to -$30.4 million in 2022, then skyrocketed by 114.73% to $4.5 million in 2023, then spiked by 682.73% to $35.0 million in 2024, then skyrocketed by 217.34% to $10.7 million in 2025.
  • Its Cash from Financing Activities stands at $10.7 million for Q3 2025, versus $2.9 million for Q2 2025 and -$7.5 million for Q1 2025.